Olmesartan monohydrate | 913529-31-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: Olmesartan monohydrate
• 英文别名: 5-(2-hydroxypropan-2-yl)-2-propyl-3-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]imidazole-4-carboxylic acid;hydrate
• CAS: 913529-31-4
• 化学式: C24H28N6O4
• 分子量: 464.5
• InChiKey: CBVAUXGQUBKMCU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.83
• 重原子数：
  34
• 可旋转键数：
  8
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  131
• 氢给体数：
  4
• 氢受体数：
  8

文献信息

• THERAPEUTIC AGENT FOR CORNEAL/CONJUNCTIVAL DISORDER
  申请人：SANTEN PHARMACEUTICAL CO., LTD.

  公开号：EP1872783A1

  公开（公告）日：2008-01-02

  An object of the present invention is to research a therapeutic agent for a keratoconjunctival disorder. A compound represented by the following general formula (1) or a salt thereof exhibits an excellent improving effect on corneal disorder models, and therefore is useful as a therapeutic agent for a keratoconjunctival disorder such as dry eyes, corneal ulcer, keratitis or conjunctivitis. In the formula, the ring Y represents a substituted or unsubstituted nitrogen-containing heterocyclic ring; R1 represents a carboxy group or a substituted or unsubstituted nitrogen-containing 5-membered heterocyclic ring; and R2 and R3 may be the same or different and represent a hydrogen atom, a substituted or unsubstituted alkyl group or a substituted or unsubstituted alkylcarbonyl group. In the formula, X represents or

  本发明的目的是研究一种角膜结膜疾病的治疗剂。由以下通式（1）代表的化合物或其盐对角膜紊乱模型有很好的改善作用，因此可用作干眼症、角膜溃疡、角膜炎或结膜炎等角膜结膜紊乱的治疗剂。式中，环 Y 代表取代或未取代的含氮杂环；R1 代表羧基或取代或未取代的含氮 5 元杂环；R2 和 R3 可以相同或不同，代表氢原子、取代或未取代的烷基或取代或未取代的烷基羰基。 式中，X 代表 或
• FAST DISSOLVING OCULAR INSERT
  申请人：University Of The Witwatersrand, Johannesburg

  公开号：EP2895153A1

  公开（公告）日：2015-07-22
• Therapeutic Agent for Keratoconjunctival Disorder
  申请人：Shibagaki Keiichi

  公开号：US20090042962A1

  公开（公告）日：2009-02-12

  An object of the present invention is to research a therapeutic agent for a keratoconjunctival disorder. A compound represented by the following general formula (1) or a salt thereof exhibits an excellent improving effect on corneal disorder models, and therefore is useful as a therapeutic agent for a keratoconjunctival disorder such as dry eyes, corneal ulcer, keratitis or conjunctivitis. In the formula, the ring Y represents a substituted or unsubstituted nitrogen-containing heterocyclic ring; R 1 represents a carboxy group or a substituted or unsubstituted nitrogen-containing 5-membered heterocyclic ring; and R 2 and R 3 may be the same or different and represent a hydrogen atom, a substituted or unsubstituted alkyl group or a substituted or unsubstituted alkylcarbonyl group. In the formula, X represents
• Fast Dissolving Ocular Insert
  申请人：UNIVERSITY OF THE WITWATERSRAND, JOHANNESBURG

  公开号：US20150209275A1

  公开（公告）日：2015-07-30

  This invention relates to a pharmaceutical dosage form, particularly to a topical ocular pharmaceutical dosage form comprising a polymeric matrix of polyethylene oxide block copolymer, preferably polyoxyethylene-polyoxypropylene block copolymer and hydroxpropyl cellulose, and a pharmaceutically active ingredient incorporated within the matrix. The invention extends to a method of manufacturing the pharmaceutical dosage form.
• [EN] FAST DISSOLVING OCULAR INSERT<br/>[FR] INSERT OCULAIRE À DISSOLUTION RAPIDE
  申请人：UNIV WITWATERSRAND JHB

  公开号：WO2014041485A1

  公开（公告）日：2014-03-20

  This invention relates to a pharmaceutical dosage form, particularly to a topical ocular pharmaceutical dosage form comprising a polymeric matrix of polyethylene oxide block copolymer, preferably polyoxyethylene-polyoxypropylene block copolymer and hydroxpropyl cellulose, and a pharmaceutically active ingredient incorporated within the matrix. The invention extends to a method of manufacturing the pharmaceutical dosage form.